Combined effect of anticancer agents and cytochrome C decorated hybrid nanoparticles for liver cancer therapy

Al Shakarchi, Wejdan and Alsuraifi, Ali and Abed, Mohammad and Abdullah, Marwan and Richardson, Alan and Curtis, Anthony and Hoskins, Clare (2018) Combined effect of anticancer agents and cytochrome C decorated hybrid nanoparticles for liver cancer therapy. Pharmaceutics, 10 (2). 48. ISSN 1999-4923 (

[thumbnail of Al-Shakarchi-etal-P2018-Combined-effect-anticancer-agents-cytochrome-C-decorated-hybrid-nanoparticles-liver-cancer-therapy]
Text. Filename: Al_Shakarchi_etal_P2018_Combined_effect_anticancer_agents_cytochrome_C_decorated_hybrid_nanoparticles_liver_cancer_therapy.pdf
Final Published Version
License: Creative Commons Attribution 4.0 logo

Download (9MB)| Preview


Hepatocellular carcinoma is an aggressive form of liver cancer that displays minimal symptoms until its late stages. Unfortunately, patient prognosis still remains poor with only 10% of patients surviving more than five years after diagnosis. Current chemotherapies alone are not offering efficient treatment, hence alternative therapeutic approaches are urgently required. In this work, we highlight the potential of combination of treatment of hepatocellular carcinoma with existing chemotherapies in combination with pro-apoptotic factor cytochrome C. In order to allow cytochrome C to cross the cellular membrane and become internalized, it has been immobilised onto the surface of hybrid iron oxide-gold nanoparticles. This novel approach has been tested in vitro on HepG2, Huh-7D and SK-hep-1 cell lines in order to elucidate potential as a possible alternative therapy with greater efficacy. The data from our studies show consistently that combining treatment of clinically used anticancer agents (doxorubicin, paclitaxel, oxaliplatin, vinblastine and vincristine) significantly increases the levels of apoptosis within the cell lines, which leads to cellular death. Hence, this combined approach may hold promise for future treatment regimes.